• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Dropout rates for phase I oncology trials remain under 10%

Dropout rates for phase I oncology trials remain under 10%

September 4, 2013
CenterWatch Staff

The overall dropout rate for oncology phase I trials is only 8%, according to a study by Cutting Edge Information. However, dropout rates tend to rise as the number of required visits increases.

The study, Phase I Clinical Trials: Optimizing Cost-Drivers for Clinical Pharmacology Programs, found the average number of patients enrolled for these trials across all therapeutic areas is 47.2.

Surveyed companies reported as few as 15 patients enrolled in their phase I trials. However, "one interviewed executive conducting a diabetes trial reported 200 enrolled patients, many more than any other trial," said Ryan McGuire, research team leader at Cutting Edge Information. "Though the diabetes trial had the highest patient enrollment, its total costs are 2.5 times less than the overall average. Patient recruitment was likely easy for this therapeutic area, and the trial required only four patient visits."

The next highest number of patients came from an oncology clinical trial. Initial patient enrollment ranged from 15 to 106, much higher than the average for phase I trials. Across other therapeutic areas, including cardiovascular, gastroenterology and women's health, average enrollment was generally between 20 and 40 patients.

The study reveals the average number of patients completing phase I trials by therapeutic area. Oncology trials align with the average dropout rate at 8%. Central nervous system/neurology trial results show a dropout rate at 7%. Women's health trials appear to have a high average dropout rate at 16%—double this study's overall average.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing